Show pageBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Association for Molecular Pathology v. Myriad Genetics: The Supreme Court Case That Unlocked Your DNA ====== **LEGAL DISCLAIMER:** This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation. ===== What is the Myriad Genetics Case? A 30-Second Summary ===== Imagine a mapmaker discovers a new, hidden island. Can they claim ownership of the island itself, forbidding anyone else from even looking at it or describing its features without paying a hefty fee? Or can they only own the unique, detailed maps they create? This is the core question behind one of the most important [[bioethics]] and [[patent_law]] cases of the 21st century: **Association for Molecular Pathology v. Myriad Genetics, Inc.** For years, a single company, Myriad, owned patents on two human genes—BRCA1 and BRCA2—which are strongly linked to hereditary breast and ovarian cancer. This meant they had a monopoly. They alone could perform tests on these genes, setting the price (over $3,000) and controlling all research. Patients couldn't get a second opinion. Scientists couldn't easily study the genes. This case, brought by a coalition of doctors, patients, and the [[aclu]], challenged whether a part of the natural human body could be owned by a corporation. In 2013, the [[supreme_court_of_the_united_states]] delivered a landmark, unanimous answer that reshaped medicine, research, and our very understanding of who owns the code of life. * **Key Takeaways At-a-Glance:** * **Natural DNA Cannot Be Patented:** The Supreme Court's core ruling in the **Myriad Genetics case** established that naturally occurring DNA segments are products of nature and cannot be patented, even if they are "isolated" from the human body. * **Opened the Door for Competition:** This decision immediately invalidated Myriad's patents on the [[brca1_and_brca2_genes]], allowing other labs to offer genetic tests, which dramatically lowered costs and increased patient access to crucial health information. * **Synthetic DNA Can Be Patented:** The Court made a critical distinction, ruling that complementary DNA (cDNA)—a synthetic, lab-created form of DNA—**is** patent-eligible because it is not a naturally occurring substance. This preserved incentives for innovation in [[biotechnology]]. ===== Part 1: The Legal Foundations of Gene Patenting ===== ==== The Story of Myriad: A Historical Journey ==== The story of the **Myriad Genetics case** doesn't begin in a courtroom, but in a laboratory during the Human Genome Project—a monumental international effort to map our entire genetic code. In the 1990s, scientists were in a race to identify specific genes linked to diseases. In 1994, a team of researchers, including some at the University of Utah and Myriad Genetics, successfully identified and sequenced the BRCA1 gene. A year later, they did the same for BRCA2. Possessing this knowledge, Myriad Genetics, in partnership with the University of Utah Research Foundation, did something that was common practice at the time: they filed for patents. They didn't just patent a method for testing the gene; they patented the "isolated" gene sequences themselves. For nearly two decades, this gave Myriad a powerful monopoly. If you were a woman with a family history of breast cancer and wanted to know if you carried the dangerous BRCA mutation, you had one option: Myriad's test. The company aggressively enforced its patents, sending cease-and-desist letters to other labs and researchers who tried to offer testing. The cost was high, and the lack of competition meant patients had no way to get a second opinion from another provider if they received a troubling result. This situation grew increasingly untenable for scientists, doctors, and patient advocates. They argued that a gene, a fundamental piece of human heredity, shouldn't be a corporate asset. In 2009, the American Civil Liberties Union (ACLU) and the Public Patent Foundation filed a lawsuit on behalf of the Association for Molecular Pathology (AMP) and a host of other plaintiffs. Their argument was simple but profound: patents on human genes were unconstitutional and violated the core principles of [[patent_law]]. The case journeyed through the lower courts with conflicting results before finally landing before the Supreme Court, setting the stage for a decision that would affect millions. ==== The Law on the Books: The "Product of Nature" Doctrine ==== The legal fight in **Myriad** centered on a single, crucial section of U.S. patent law: `[[35_usc_101]]`. This statute defines what is eligible for a patent. It states that anyone who "invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent." The courts have long interpreted this to mean there are three things you **cannot** patent: * Laws of nature (like gravity) * Natural phenomena (like a wildflower) * Abstract ideas (like a mathematical formula) This is known as the **"product of nature" doctrine**. You can't patent something that already exists in the wild. You can't get a patent on gold, even if you're the first person to find a huge gold deposit. However, you *could* potentially patent a new and inventive method for extracting that gold. Myriad's argument was that by "isolating" the BRCA1 and BRCA2 genes from the surrounding genetic material in the human body, they had created something "new" and distinct from what exists in nature. They claimed the isolated gene was a patentable "composition of matter." The plaintiffs countered that isolating a gene is like taking a kidney out of a body—it's still a human kidney. The fundamental information—the genetic sequence—is identical, a product of nature, and therefore not eligible to be patented. The Supreme Court's entire decision would hinge on which of these interpretations it found more compelling. ==== The Global Impact: Gene Patenting Around the World ==== The U.S. Supreme Court's decision sent ripples across the globe, as many countries were grappling with the same ethical and legal questions. While the Myriad ruling is binding only in the United States, its influence has been significant. ^ **Jurisdiction** ^ **Stance on Patenting Natural DNA** ^ **What It Means for You** ^ | United States | **Not Patentable.** The `[[association_for_molecular_pathology_v_myriad_genetics]]` ruling established that isolated but otherwise unaltered human genes are "products of nature" and cannot be patented. | In the U.S., you have access to competitive genetic testing from multiple providers for naturally occurring genes like BRCA1/2. | | Europe | **Generally Patentable (with limits).** The EU's Biotechnology Directive (98/44/EC) allows for patenting isolated genes if they have a specific, disclosed industrial application. The "product of nature" bar is lower than in the U.S. | A company in Europe might still hold a patent on an isolated human gene, potentially limiting testing options or research within the EU. | | Australia | **Not Patentable.** Inspired in part by the U.S. Myriad case, the High Court of Australia ruled in 2015 in *D'Arcy v Myriad Genetics Inc* that isolated nucleic acids are not patentable inventions. | Similar to the U.S., the Australian ruling promotes open access and competition for genetic diagnostic testing. | | Canada | **Not Patentable.** In 2016, a Canadian Federal Court ruling in a case involving the Children's Hospital of Eastern Ontario and human genes effectively invalidated gene patents in Canada, aligning with the U.S. precedent. | The legal landscape in Canada also favors patient access over monopolistic gene patents. | ===== Part 2: Deconstructing the Court's Core Rulings ===== The Supreme Court's unanimous opinion, written by Justice Clarence Thomas, was a masterclass in drawing fine but critical distinctions. It didn't just give a simple "yes" or "no" but carefully dissected the science to create a new legal framework. === Element: Naturally Occurring DNA === The Court addressed Myriad's primary claim: that by isolating the BRCA genes, they had created something patentable. The Court firmly rejected this. Justice Thomas wrote that Myriad "did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes." The location and order of the nucleotides existed in nature before Myriad found them. The Court used a powerful analogy: a person who discovers a new plant in the wild cannot patent the plant itself. "Myriad's principal contribution was uncovering the precise location and genetic sequence," the opinion states, which is a discovery, not an invention. Therefore, **isolated, naturally occurring DNA is a product of nature and not patent-eligible.** === Element: Isolated DNA === This was the central battleground. Myriad's lawyers argued that the chemical act of severing the bonds to "isolate" the gene from its chromosome made it a new chemical entity. The Court disagreed. They found that this process alone did not create a "new composition of matter." The crucial element—the information contained within the gene's sequence—remained unchanged. This part of the ruling was a huge victory for the plaintiffs and established that simply removing a natural product from its surrounding environment is not an act of invention that warrants a [[patent]]. === Element: Complementary DNA (cDNA) === Here, the Court pivoted. In a laboratory, scientists can create a synthetic version of a gene called complementary DNA, or cDNA. This is done by taking the messenger RNA (mRNA) from a cell and using an enzyme to create a DNA strand from it. Crucially, this process strips out the non-coding regions of the gene (introns) that exist in natural DNA. The Supreme Court found that **cDNA is patent-eligible**. Why? Because the lab technician "unquestionably creates something new when cDNA is made." An exon-only molecule is not found in nature. This distinction was vital. It allowed the Court to invalidate the patents on the natural genes that were harming patients, while still preserving a path for biotechnology companies to protect their investment in genuinely new, lab-created genetic tools and therapies. This preserved the financial incentive for innovation that the [[patent_system]] is designed to foster. === Element: The "Product of Nature" Doctrine === Ultimately, the **Myriad Genetics case** was a powerful reaffirmation of the `[[product_of_nature_doctrine]]` in the age of biotechnology. The Court drew a bright line: you cannot patent things you find in nature, but you can patent things you invent in a lab. The decision clarified that the key is whether the invention has "markedly different characteristics from any found in nature." Isolated DNA failed this test; cDNA passed it. This principle now guides patent examiners at the `[[uspto]]` (U.S. Patent and Trademark Office) when they review applications for everything from genetic sequences to newly discovered microorganisms. ===== Part 3: The Myriad Ruling's Impact on You: A Patient's and Innovator's Guide ===== This Supreme Court decision wasn't just an abstract legal debate; it had immediate, real-world consequences for millions of people. ==== For Patients and Families: Your Right to Your Genetic Information ==== The most direct impact of the **Myriad** ruling was on patients. Before the decision, Myriad's BRCA test cost between $3,000 and $4,000. Within months of the Supreme Court's ruling, multiple companies entered the market. - **Step 1: The Invalidation of Patents:** On June 13, 2013, the day of the decision, Myriad's monopoly vanished. - **Step 2: The Rush of Competition:** Companies like Ambry Genetics, Gene by Gene, and LabCorp immediately announced they would begin offering BRCA testing. - **Step 3: A Dramatic Price Drop:** With competition, the price for BRCA testing plummeted. Today, these tests can often be performed for a few hundred dollars, and are frequently covered by insurance. - **Step 4: The Right to a Second Opinion:** For the first time, patients who received a positive or ambiguous result from one lab could have their test confirmed by another, an essential part of quality medical care. - **Step 5: Expansion of Genetic Panels:** Freed from patent restrictions, labs began offering multi-gene panels that test for BRCA1, BRCA2, and other cancer-risk genes simultaneously, providing a more comprehensive risk assessment for the same or lower cost. The public awareness driven by figures like **Angelina Jolie**, who wrote a famous op-ed in the New York Times about her decision to undergo preventative surgery based on her BRCA status, amplified the importance and accessibility of this testing post-**Myriad**. ==== For Researchers and Innovators: The New Rules of Biotech IP ==== For those in the biotechnology industry, the ruling provided much-needed clarity, even if it wasn't the outcome the incumbent patent-holders wanted. * **Focus on Application, Not Discovery:** The decision shifted the focus of [[intellectual_property]] in genetics. Companies can no longer patent the genes themselves; instead, they must patent new applications, diagnostic methods, or therapeutic uses for those genes. * **Protection for cDNA and Synthetic Biology:** The ruling that cDNA is patentable ensured that the booming field of synthetic biology still had strong IP protections. This encourages the development of new gene therapies, synthetic DNA for vaccines (like mRNA vaccines), and other cutting-edge technologies. * **Clarity for Diagnostic Methods:** While **Myriad** focused on "composition of matter," it worked in tandem with the 2012 case `[[mayo_v_prometheus]]`, which limited patents on diagnostic methods that are too close to a "law of nature." Together, these cases tell innovators that to get a patent, they must invent a truly novel tool or process, not just observe a natural correlation. ===== Part 4: Landmark Cases That Shaped Today's Law ===== The **Myriad** decision did not happen in a vacuum. It was the culmination of decades of legal and scientific development, standing on the shoulders of previous landmark cases. ==== Precedent Case: Diamond v. Chakrabarty (1980) ==== This was the case that opened the floodgates for the biotechnology industry. Ananda Chakrabarty, a microbiologist working for General Electric, had developed a genetically engineered bacterium capable of breaking down crude oil. The `[[uspto]]` rejected his patent application on the grounds that living things could not be patented. The Supreme Court, in a 5-4 decision, disagreed. Chief Justice Burger famously wrote, "anything under the sun that is made by man" is patentable. The Court held that Chakrabarty's bacterium was not a "product of nature" but a man-made invention with "markedly different characteristics." This case established the principle that life forms could be patented, setting the stage for patents on everything from plants to, eventually, human genes. ==== Precedent Case: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012) ==== Just one year before **Myriad**, the Supreme Court decided *Mayo v. Prometheus*, a case that significantly tightened the rules for patenting medical diagnostic methods. Prometheus had patented a method for determining the proper dosage of a certain drug by observing a natural correlation in the patient's blood. The Court unanimously struck down the patent, ruling that it was essentially a patent on a law of nature. The steps involved were considered routine and not inventive enough to transform the natural law into a patent-eligible application. This decision signaled the Court's growing skepticism of patents that seemed to lock up basic scientific principles and heavily influenced the Court’s thinking in **Myriad**. ==== The Main Event: Association for Molecular Pathology v. Myriad Genetics (2013) ==== This case was the final act in the drama. The legal question was sharp: Is "isolated" human DNA patentable? The court's holding was equally sharp: No. But is synthetic cDNA patentable? Yes. The ruling threaded the needle, seeking to balance the need to reward true invention with the public's interest in accessing fundamental scientific knowledge. By invalidating the gene patents, the Court prevented the privatization of the human genome. By upholding cDNA patents, it ensured that the biotech industry's incentives for creating new medicines and tools remained intact. It was a pragmatic and powerful decision that immediately and profoundly impacted science, medicine, and law. ===== Part 5: The Future of Gene-Related Law ===== The **Myriad** case answered a huge question, but it also opened the door to new ones as technology continues to accelerate. ==== Today's Battlegrounds: Current Controversies and Debates ==== The legal and ethical debates in genetics have moved beyond simple gene sequencing. * **CRISPR and Gene Editing:** The development of powerful gene-editing technologies like CRISPR has created a new patent battleground. Here, the patents are not on the genes themselves, but on the inventive *methods* and *systems* used to edit them. These patent fights, like the one between the Broad Institute and UC Berkeley, are incredibly complex and will determine who controls the future of genetic medicine. * **Diagnostic Method Patents:** The line between a patent-ineligible natural law and a patent-eligible diagnostic application remains blurry after *Mayo* and *Myriad*. Innovators complain that the `[[uspto]]` is rejecting too many legitimate inventions, while critics worry that allowing such patents will stifle medical progress. Congress has considered legislation to clarify `[[35_usc_101]]`, but no consensus has been reached. * **Data and Privacy:** As millions of people undergo genetic testing, the new frontier is the data itself. Who owns your genetic data? How can it be used for research? What are the `[[privacy_rights]]` involved? These are legal and ethical questions that are now at the forefront of `[[health_law]]`. ==== On the Horizon: How Technology and Society are Changing the Law ==== Looking ahead, the legal framework established by **Myriad** will be tested by new technologies. * **Artificial Intelligence:** AI is now being used to analyze vast genetic datasets to predict disease risk and identify targets for new drugs. This raises novel [[intellectual_property]] questions: Can an AI be an "inventor"? Can a correlation discovered solely by an AI be patented? * **Personalized Medicine:** The future of medicine lies in treatments tailored to an individual's unique genetic makeup. The **Myriad** decision helps ensure that the foundational genetic information needed for this revolution remains in the public domain, but patents on the specific drugs and delivery systems will be fiercely contested. * **Synthetic Biology:** As our ability to write DNA from scratch improves, the distinction between natural and artificial will become even more complex, creating new challenges for the `[[patent_system]]` and the "product of nature" doctrine. ===== Glossary of Related Terms ===== * **[[aclu]]:** The American Civil Liberties Union, a non-profit organization that was a lead plaintiff in the case against Myriad. * **[[bioethics]]:** The study of ethical issues emerging from advances in biology and medicine. * **[[biotechnology]]:** The use of living systems and organisms to develop or make products. * **[[brca1_and_brca2_genes]]:** Human genes that, when mutated, are associated with a significantly higher risk of hereditary breast and ovarian cancer. * **[[cdna]]:** Complementary DNA, a synthetic, lab-created DNA molecule that contains only the protein-coding regions (exons) of a gene. * **[[crispr]]:** A powerful and precise gene-editing technology that allows scientists to modify DNA sequences. * **[[dna]]:** Deoxyribonucleic acid, the molecule that carries the genetic instructions for the development, functioning, growth, and reproduction of all known organisms. * **[[intellectual_property]]:** A category of property that includes intangible creations of the human intellect, such as patents, copyrights, and trademarks. * **[[isolated_dna]]:** A segment of DNA that has been chemically separated from the chromosome in which it naturally resides. * **[[patent]]:** A government-granted exclusive right to an inventor, preventing others from making, using, or selling the invention for a limited period. * **[[patent_eligibility]]:** The legal standard for determining whether a particular invention or discovery is the kind of subject matter that can be patented, governed by `[[35_usc_101]]`. * **[[product_of_nature_doctrine]]:** A core principle in patent law stating that naturally existing substances and phenomena are not patentable. * **[[supreme_court_of_the_united_states]]:** The highest court in the U.S. federal judiciary, which issued the final, unanimous ruling in the Myriad case. * **[[uspto]]:** The United States Patent and Trademark Office, the federal agency responsible for issuing patents. ===== See Also ===== * [[intellectual_property]] * [[patent_law]] * [[supreme_court_cases]] * [[bioethics]] * [[health_law]] * [[mayo_v_prometheus]] * [[diamond_v_chakrabarty]]